The pharmaceutical group Sanofi Pasteur, a global leader in vaccines, is producing a new vaccine for adults as a booster following a previous vaccination, for the combined prevention of diphtheria, tetanus, and poliomyelitis.
Built on the verb “revaccinate,” Revaxis refers, on one hand, directly to the organic substance specifically designed to elicit a preventive immune response against an infectious disease, and on the other hand, to the use of the medication intended for booster vaccinations.
